Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis Allen, P., Chen, Q. C., Lu, X., O'Shea, K., Chmiel, J., Sukhanova, M., Slonim, L., Savas, H., Mou, E., Pro, B., Evens, A. M., Palmer, B., Advani, R., Gordon, L. I., Winter, J. N. AMER SOC HEMATOLOGY. 2021
View details for DOI 10.1182/blood-2021-147042
View details for Web of Science ID 000736398801008